Methohexital
Methohexital is a short-acting barbiturate general anaesthetic used for the induction of anaesthesia and, in selected clinical settings, for brief procedures or electroconvulsive therapy (ECT). It works by enhancing the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, producing rapid central nervous system depression and loss of consciousness. It is commonly available as a powder for reconstitution and intravenous administration. Possible adverse effects include respiratory depression, low blood pressure, involuntary muscle movements, nausea, and prolonged recovery in some patients. Important precautions include continuous monitoring of breathing, oxygenation, and cardiovascular function, with particular care in patients with respiratory or cardiovascular disorders. Methohexital must be administered by trained anaesthesia professionals in a properly equipped clinical setting.
Methohexital was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Methohexital, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Methohexital from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Methohexital, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
